To further confirm the involvement of the dysregulated NF-κB signaling pathway in the synergized anti-cancer effect mediated by Aspirin and Cisplatin co-treatment, we used Lipopolysaccharides (LPS) [35, 36] or the 6-amino-4-(4-phenoxyphenylethylamino) quinazoline (QNZ) [37] to respectively activate or suppress NF-κB signaling in colon cancer cells following the co-treatment of Aspirin and Cisplatin and analyzed cell viability changes. Here, NFKB1 is linked to colonic neoplasm.